Program
FLT3 Inhibitor XY0206
Also written as “XY0206” and “[14C]XY0206”.
Its studies are mostly in Leukemia, Myeloid, Acute, led by Shijiazhuang Yiling Pharmaceutical.
Furthest: phase 3, since May 17, 20235 company-led studies, 3 open or runningNext primary completion: Jul 1, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shijiazhuang Yiling Pharmaceutical | 53 open or running | phase 3since May 17, 2023 | Aug 8, 2018 | Jul 1, 2027phase 3 · NCT05876832 |
Also a collaborator on its studies: Proswell Medical and Tigermed Consulting.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 8, 2018First study: phase 1 study in Advanced or Metastatic Solid TumoursFirst studyNCT03658070 · 34 enrolled · China
- Jul 1, 2020Phase 1 study in Leukemia, Myeloid, AcuteNCT04471064 · 60 planned · China
- May 17, 2023Phase 3 study in Acute Myeloid Leukemia With FLT3/ITD MutationNCT05876832 · 312 planned
- Feb 7, 2025Phase 1 study in Metabolism of Radioactive SubstancesNCT06823232 · 6 enrolled · China
- Aug 26, 2025Phase 1 study in Acute Myeloid Leukemia With FLT3/ITD MutationNCT07162116 · 45 planned · China
Ahead
- Jul 1, 2027Primary completion: phase 3 study in Acute Myeloid Leukemia With FLT3/ITD MutationNCT05876832
TargetBeta
FLT3 →read by rule
“A selective inhibitor of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) ”NCIt, by rule
Other programs on FLT3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| jaktinibrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 31 |
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
| gilteritinibrule | Astellas Pharma | phase 3 | 20 |
| pacritinibrule | Swedish Orphan Biovitrum | phase 3 | 18 |
| AXL/FLT3/VEGFR2 Inhibitor KC1036rule | beijing-konruns-pharmaceutical-co-ltd | phase 3 | 7 |
| flonoltinibrule | Chengdu Zenitar Biomedical Technology | phase 3 | 7 |
| nefextinibrule | maxinovel-pty-ltd | phase 2 | 9 |
| Anti-FLT3/CD3 Bispecific Antibody CLN-049rule | cullinan-therapeutics-inc | phase 2 | 2 |
| flonoltinib maleaterule | Chengdu Zenitar Biomedical Technology | phase 2 | 2 |
| HPB-092rule | hangzhou-polymed-biopharmaceuticals-inc | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07162116Acute Myeloid Leukemia With FLT3/ITD Mutation · China | 1 | Recruiting | Dec 1, 2025 | 45 |
| NCT06823232Metabolism of Radioactive Substances · China | 1 | Completed | Dec 5, 2024 | 6 |
| NCT05876832Acute Myeloid Leukemia With FLT3/ITD Mutation | 3 | Not yet recruiting | Jul 1, 2027 | 312 |
| NCT04471064Leukemia, Myeloid, Acute · China | 1 | Recruiting | Feb 2024 | 60 |
| NCT03658070Advanced or Metastatic Solid Tumours · China | 1 | UNKNOWN | Dec 2020 | 34 |
How it is read
Names in the registry
- “XY0206”, 4 entries
- “[14C]XY0206”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.